Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Durect ( (DRRX) ) has issued an update.
DURECT Corporation received a notice from Nasdaq on January 9, 2025, indicating that its stock price had fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company was initially given until July 8, 2025, to comply, and later received an additional 180-day grace period until January 5, 2026. DURECT plans to monitor its stock price and may implement a reverse stock split if necessary to meet the requirements, as failure to regain compliance could result in delisting.
The most recent analyst rating on (DRRX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Durect stock, see the DRRX Stock Forecast page.
Spark’s Take on DRRX Stock
According to Spark, TipRanks’ AI Analyst, DRRX is a Neutral.
The overall stock score is primarily influenced by significant financial challenges, including declining revenues and persistent losses. Technical analysis provides mixed signals, with some short-term bullish indicators but a bearish long-term trend. Valuation concerns are exacerbated by a negative P/E ratio, highlighting potential overvaluation risks. The lack of positive earnings call data or corporate events further limits the score.
To see Spark’s full report on DRRX stock, click here.
More about Durect
DURECT Corporation operates in the biopharmaceutical industry, focusing on the development of innovative therapeutics. The company is known for its proprietary drug delivery technology and its efforts to address unmet medical needs.
Average Trading Volume: 107,988
Technical Sentiment Signal: Sell
Current Market Cap: $20.12M
See more insights into DRRX stock on TipRanks’ Stock Analysis page.